Navigation Links
Intarcia and Quintiles Sign Letter of Intent for Innovative Global Collaboration to Advance ITCA 650 in Type 2 Diabetes
Date:10/21/2011

HAYWARD, Calif., Oct. 21, 2011 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the signing of a letter of intent with Quintiles, the world's leading biopharmaceutical services company, to collaborate on the global Phase 3 program for Intarcia's ITCA 650 (DUROS® subcutaneous continuous delivery of exenatide). The program aims to demonstrate multiple advancements in GLP-1 therapy to better address the unmet needs of the almost 350 million people worldwide suffering from Type 2 diabetes – a debilitating and deadly disease. ITCA 650 utilizes a matchstick-size, subcutaneous mini-pump that allows smooth continuous delivery of exenatide from a once-yearly placement. This novel delivery of GLP-1 therapy has been shown to improve HbA1c, weight loss, tolerability and also virtually ensures patient compliance and adherence. By improving the clinical profile and removing the self-injection barrier to use, ITCA 650 would also hold promising potential for use in earlier lines of therapy.

(Logo: http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO)

Upon execution of the definitive agreement, Quintiles will initiate a global Phase 3 program including the six clinical studies that will form the basis of international regulatory submissions. This alliance is the first of a planned two-step partnering strategy, as Intarcia finalizes its late-stage discussions with global pharma companies in the diabetes field. This will form a unique and powerful three-way alliance dedicated to the development and commercialization of ITCA 650 around the world.

"The prospect of a once-yearly, improved GLP-1 therapy could be a game-changer in one of the industry's largest and most rapidly growing therapeutic categories," said Kurt Graves, Executive Chairman of Intarcia's Board of Directors. "P
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
3. Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
4. Intarcia Therapeutics Executive Chairman Kurt Graves to Present at 29th Annual JP Morgan Healthcare Conference
5. Intarcia Announces Presentations of Three Clinical Abstracts at the 47th Annual Meeting of the European Association for the Study of Diabetes
6. Intarcia Presents Compelling 48-week Results for ITCA 650 - Data Underlines the Promise to Become the First Injection-free GLP-1 Therapy at the 47th Annual EASD Meeting in Lisbon
7. Dr. Derek Winstanly of Quintiles to Serve as 2009 ACRO Chair; Mr. William Sharbaugh of PPD to Be Chair-Elect
8. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Tone Deafness Explained, from the Harvard Health Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Advanced Photonix ® (NYSE MKT: API) will ... results on Monday, August 11, 2014. A press release announcing ... the market and the Company will host a live audio ... on the same day. Participating in the call ... Rob Risser (COO and Director), and Jeff Anderson ...
(Date:7/30/2014)... July 30, 2014  Unilife Corporation ("Unilife" or ... developer and supplier of injectable drug delivery systems, ... capacity, R&D, and facilities in response to increasing ... products and services. During the fourth quarter of ... million in capital expenditures and R&D above normal ...
(Date:7/30/2014)... 30, 2014 /PRNewswire-iReach/ -- Transluminal Technologies LLC, a ... company, has announced today that they have received ... Closure Device. Velox CD™ provides a safe and ... femoral procedures. The single size velox CD™ is ... from 5F to 8F.  Velox CD™ ...
Breaking Medicine Technology:Advanced Photonix to Webcast Fiscal 2015 First Quarter Earnings 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2
... Calif., March 7, 2012  Isis Pharmaceuticals, Inc. (NASDAQ: ... 1 study of ISIS-STAT3Rx, a Generation 2.5 antisense drug ... of signal transducer and activator of transcription 3 (STAT3). ... cancers, ISIS-STAT3Rx has the potential to be broadly useful ...
... March 7, 2012  Solta Medical, Inc. (NASDAQ: ... market, today provided an update on the launch of ... approved by the FDA. A majority ... comprised of leading plastic surgeons and dermatologists, who received ...
Cached Medicine Technology:Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 2Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 3Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx 4Solta Medical Provides Update on Liposonix Launch 2Solta Medical Provides Update on Liposonix Launch 3Solta Medical Provides Update on Liposonix Launch 4
(Date:7/31/2014)... Beverly Hills, CA (PRWEB) July 31, 2014 ... president George W. Bush recently underwent partial knee replacement surgery ... right knee less than two months earlier. The story also ... between the procedures and hopes to be back on the ... replacement surgery highlights the benefits of partial knee replacement. ...
(Date:7/31/2014)... 2014 Recognizing that today’s medical students ... Healthcare Conference announced today its student discount program. ... medicine or a healthcare-related field, as well as medical ... discounts for the conference, scheduled for September 17-20, 2014 ... Resort. , “As a future Registered Dietitian, ...
(Date:7/31/2014)... ProtonPACS, a division of Radsource, has signed ... Health Association (NRHA), company officials announced today. The partnership ... of rural health providers nationwide. , “We are proud ... Dr. Mark Awh, President of Radsource. “While we are ... are also looking forward to learning from all of ...
(Date:7/31/2014)... The shale gas development that has vaulted ... U.S. natural gas production has raised concerns that local ... similar to previous resource extraction experiences in Pennsylvania’s history. ... & Jefferson College’s (W&J) Center for Energy Policy & ... that the gas boom in Pennsylvania is still underway, ...
(Date:7/31/2014)... (August 1, 2014) While it is known that members ... use alcohol, a new study finds that female enlistees ... than their civilian counterparts. This study was published today ... journal published on behalf of the Inter-University Seminar on ... and Lucky Tedrow studied surveys of nearly 9,000 men ...
Breaking Medicine News(10 mins):Health News:George W. Bush’s Surgery Highlights the Benefits of Partial Knee Replacement 2Health News:Student Discounts Offered for International Plant-based Nutrition Healthcare Conference 2Health News:Student Discounts Offered for International Plant-based Nutrition Healthcare Conference 3Health News:ProtonPACS Announces Pipeline Partnership with the National Rural Health Association. 2Health News:Pennsylvania’s Shale Gas: Examining the Boom and Bust Cycle 2Health News:Pennsylvania’s Shale Gas: Examining the Boom and Bust Cycle 3Health News:Women in military less likely to drink than civilian women 2
... James "Buster" Douglas, former World Heavyweight Boxing Champion, ... brand new inspirational diabetic diet cookbook. "Take a ... Bar-B-Q Knockout Diabetes Diet," available now on Amazon.com ... to order for Mother,s Day, Sunday, May 10, ...
... Partners, Inc. and its affiliate, JLL Patheon Holdings, LLC (collectively, ... on May 7, 2009 (the "Expiry Time") 31,411,927 Restricted Voting ... deposited to JLL,s offer to acquire, at a price of ... and outstanding Restricted Voting Shares of Patheon (the "Offer"). As ...
... Universal Capital Management, Inc. (OTC Bulletin Board: UCMT), ... management and strategic growth resources to emerging growth ... ("Vystar") and Alatech Healthcare, LLC announced 510(k) clearance ... to market and sell Alatech,s Envy(TM) condom manufactured ...
... less cardiovascular disease than those who smoke, according ... and women in Norway. Smoking, say the investigators, ... from various causes. , The results, presented in ... studies have indicated, but, says investigator Professor Haakon ...
... preventive measures identified by the European Heart Health ... of EuroPRevent 2009, the congress of the European ... takes place in Stockholm, Sweden, on 6-9 May. ... is shown to improve markers of heart disease ...
... Netherlands: New research that uses an innovative approach to study, ... exercise habits to the development of the obesity epidemic has ... since the 1970s was virtually all due to increased energy ... has been caused by excess calorie intake and how much ...
Cached Medicine News:Health News:President Obama's New Knockout Mother's Day Message from Champ 2Health News:JLL Announces Extension of Its Offer To Acquire Patheon and Take Up of Deposited Restricted Voting Shares 2Health News:JLL Announces Extension of Its Offer To Acquire Patheon and Take Up of Deposited Restricted Voting Shares 3Health News:Universal Capital Management Reports Vystar(TM) Corporation Receives FDA Clearance for Envy(TM) Natural Rubber Latex Condom Made with Vytex(TM) NRL 2Health News:Universal Capital Management Reports Vystar(TM) Corporation Receives FDA Clearance for Envy(TM) Natural Rubber Latex Condom Made with Vytex(TM) NRL 3Health News:Universal Capital Management Reports Vystar(TM) Corporation Receives FDA Clearance for Envy(TM) Natural Rubber Latex Condom Made with Vytex(TM) NRL 4Health News:30-year follow-up study: 'Tremendous' impact of smoking on mortality and cardiovascular disease 2Health News:More evidence for the benefit of exercise in cardiovascular disease -- and even in heart failure 2Health News:More evidence for the benefit of exercise in cardiovascular disease -- and even in heart failure 3Health News:Increased food intake alone explains the increase in body weight in the United States 2Health News:Increased food intake alone explains the increase in body weight in the United States 3
Printed with large 20/200 E on one side and a series of five 20/20 tumbling Es on the other- calibrated to a 20 ft. distance. May be used to test and train peripheral awareness....
... 2/25 is an economically priced 2-channel ... and research use in the fields ... neurophysiology, biology, zoology, biochemistry and biomedical ... ADInstruments signal conditioners and transducers. Two ...
... The PowerLab/4SP is a high-performance data ... of research applications including human and animal ... biomedical engineering. The unit is capable of ... speeds (up to 200 000 samples per ...
... Worth 4 Dot with 955R Red/Green ... the presence of binocular vision. Consists ... illuminated discs: two green, one red ... at any distance. Patient wears red/green ...
Medicine Products: